# Anlotinib and Irinotecan for Ewing Sarcoma

> **NCT03416517** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Peking University People's Hospital** · enrollment: 47 (estimated)

## Conditions studied

- Ewing's Tumor Metastatic

## Interventions

- **DRUG:** Anlotinib
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT03416517
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-01-22
- **Primary completion:** 2020-02
- **Final completion:** 2020-12
- **Target enrollment:** 47 (ESTIMATED)
- **Last updated:** 2019-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03416517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03416517, "Anlotinib and Irinotecan for Ewing Sarcoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03416517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*